KITE-363 CAR-T Trial at Australian Sites for Refractory Lupus
Key Questions
What is the KITE-363 CAR-T trial for refractory lupus in Australia?
The KITE-363 trial (NCT07038447) is a Phase 1 study evaluating CAR-T therapy in participants with refractory autoimmune diseases, including steroid-resistant Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN). It is recruiting at Australian sites as part of a basket autoimmune study.
Which Australian hospitals are participating in the KITE-363 trial?
The trial is recruiting refractory SLE/LN patients at Concord Hospital in Sydney and St Vincent's Hospital in Fitzroy. These sites focus on steroid-resistant cases.
Who is eligible for the KITE-363 trial at Australian sites?
Eligibility targets patients with refractory SLE or LN who are steroid-resistant. The Phase 1 basket study (NCT07038447) provides key access information for advocates tracking novel therapies.
Phase 1 trial (NCT07038447) recruiting refractory SLE/LN patients at Concord Hospital (Sydney) and St Vincent's (Fitzroy). Targets steroid-resistant cases in basket autoimmune study. Key access intel for advocates tracking novel therapies and policy needs.